Large pooled analysis reveals no safety concerns with PCSK9-inhibitor
Jennifer Robinson (University of Iowa, Iowa City, IA, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs In a pooled analysis of 14 trials with PCSK9-inhibitor alirocumab, in over 5000 patients who achieved LDL <25 of <15 mg/dL, followed for up to 2 years, no safety signals were observed.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.